The majority of multiple sclerosis patients receive disease-modifying treatment.
By Inês Guerra, Analyst
26 July 2016
I joined Datamonitor Healthcare as an analyst in early 2015, having completed a Master’s degree in Pharmaceutical Scie...
Read full bio
Datamonitor Healthcare’s survey of 231 neurologists indicates that disease-modifying therapies (DMTs) are a key component of treatment practices in multiple sclerosis (MS), particularly during the relapsing-remitting phase of the disease. On average, 85% of relapsing-remitting MS patients are treated with DMTs. This was an expected finding: most DMTs act through anti-inflammatory pathways, so they are most useful in patients still experiencing inflammatory events, like clinical relapses. On the other hand, the mean DMT use in progressive MS is lower, likely due to the current lack of effective disease-modifying options for these patients. The higher DMT use in secondary progressive MS (64%) over primary progressive MS (50%) is also not surprising: as these patients can experience occasional relapses, they could still benefit from these drugs.
Trends in the use of DMTs appear largely consistent across the seven surveyed markets, with few exceptions. The UK is notable by displaying a significantly lower proportion of MS patients being treated with DMTs – particularly within the progressive subtypes. This lower DMT use is likely related to the existing NICE recommendations, which can restrict DMTs’ licensed patient population to ensure a cost-effective use of NHS resources.
Get your free demo of Datamonitor Healthcare today. Simply fill out the form to the right >>>